Table 1 Baseline characteristics
Variable | SGLT2i patients (n = 99) | GLP-1RA patients (n = 130) | SGLT2i + GLP-1RA patients (n = 214) | P-value |
|---|---|---|---|---|
Age (years) | 68 (63–73) Min = 57; Max = 76 | 67 (61–70) Min = 54; Max = 73 | 70 (64–75) Min = 55; Max = 79 | < 0.0001 |
Male, n (%) | 64 (64.6) | 78 (60) | 131 (61.2) | 0.835 |
BMI (kg/m2) | 28 (27–30) Min = 25; Max = 33 | 28 (27–29) Min = 15; Max = 31 | 28 (27–29) Min = 24; Max = 32 | 0.005 |
Diabetes duration (years) | 15 (13–16.5) Min = 3; Max = 24 | 14 (13–16) Min = 3; Max = 24 | 15 (14–17) Min = 3; Max = 24 | 0.0005 |
Glucose (mg/dL) | 137 (128–148) Min = 103; Max = 199 | 137 (128–155) Min = 99; Max = 234 | 189 (170.3–204) Min = 101; Max = 294 | < 0.0001 |
HbA1c baseline | 6.7 (6.5–6.8) Min = 6; Max = 9 | 6.7 (6.5–6.9) Min = 6.0; Max = 6.90 | 8.6 (7.8–9.6) Min = 6.4; Max = 13 | < 0.0001 |
Total cholesterol (mg/dL) | 211 (199–221) Min = 171; Max = 289 | 213 (199.8–222) Min = 82; Max = 274 | 213 (202–227) Min = 72; Max = 279 | 0.275 |
LDL cholesterol (mg/dL) | 139 (124.3–148.6) Min = 7.2; Max = 200.6 | 134.9 (121–144) Min = 88.3; Max = 193.7 | 135.9 (122.1–146.6) Min = 85.6; Max = 216.55 | 0.157 |
HDL cholesterol (mg/dL) | 38 (35–40) Min = 30; Max = 45 | 38 (36–40) Min = 30; Max = 45 | 38 (35–40) Min = 30; Max = 46 | 0.351 |
Triglycerides (mg/dL) | 193 (183–208.5) Min = 159; Max = 265 | 193 (182–213) Min = 159; Max = 266 | 211 (197–224) Min = 163; Max = 293 | < 0.0001 |
Creatinine (mg/dL) | 1 (0.9–1.1) Min = 0.7; Max = 1.3 | 1 (1–1.1) Min = 0.1; Max = 1.30 | 1 (1–1.1) Min = 0.1; Max = 1.3 | 0.173 |
Troponin (ng/L) | 14 (13.8–15) Min = 9; Max = 21 | 14.1 (13.7–15.8) Min = 12; Max = 18 | 14.2 (13.8–15.3) Min = 12; Max = 18 | 0.877 |
Lesion length (mm) | 20.3 (19.3–22.3) Min = 17.3; Max = 25.3 | 20.3 (19.3–22.3) Min = 17.3; Max = 25.30 | 21.2 (19.3–22.3) Min = 16.2; Max = 27.3 | 0.855 |
Ref diameter | 2.7 (2.5–2.9) Min = 1.84; Max = 4.74 | 2.8 (2.6–2.9) Min = 2.5; Max = 2.20 | 2.8 (2.6–2.9) Min = 2.3; Max = 3.2 | 0.736 |
MLD (mm) | 1.2 (1.1–1.3) Min = 0.7; Max = 1.5 | 1.1 (1.1–1.2) Min = 0.80; Max = 1.6 | 1 (0.9–1.1) Min = 0.1; Max = 9 | < 0.0001 |
Post-stent MLD (mm) | 2.5 (2–2.7) Min = 1.7; Max = 3.5 | 2.6 (2–2.7) Min = 2.00; Max = 3.10 | 2.6 (2–2.7) Min = 2; Max = 3.2 | 0.273 |
STEMI, n (%) | 41 (41.4) | 15 (11.5) | 90 (42.1) | 0.990 |
Hypertension, n (%) | 63 (63.6) | 95 (73.1) | 131 (61.2) | 0.917 |
Dyslipidemia, n (%) | 37 (37.4) | 50 (38.5) | 87 (40.7) | 0.837 |
Smokers, n (%) | 10 (10.1) | 15 (11.5) | 23 (10.7) | 0.940 |
Metformin, n (%) | 76 (76.8) | 100 (76.9) | 166 (77.6) | 0.984 |
DPP-IV inhibitors, n (%) | 9 (9) | 6 (4.6) | 23 (10.7) | 0.141 |
Thiazolidinediones, n (%) | 9 (9) | 14 (10.7) | 20 (9.3) | 0.889 |
Beta-blockers, n (%) | 52 (52.5) | 68 (52.3) | 108 (50.5) | 0.920 |
ARBs, n (%) | 39 (39.4) | 50 (38.5) | 81 (37.9) | 0.966 |
ACE inhibitors, n (%) | 42 (42.4) | 55 (42.3) | 93 (43.5) | 0.973 |
Calcium channel blockers, n (%) | 31 (31.3) | 44 (33.8) | 68 (31.8) | 0.899 |
Statin, n (%) | 60 (60.6) | 79 (60.8) | 133 (62.1) | 0.952 |
Diuretics, n (%) | 26 (26.3) | 35 (26.9) | 62 (29) | 0.855 |
Insulin, n (%) | 35 (35.4) | 48 (36.9) | 81 (37.9) | 0.913 |
Antiplatelet drugs, n (%) | 64 (64.6) | 82 (63.1) | 133 (62.1) | 0.879 |
Anticoagulant drugs, n (%) | 22 (22.2) | 22 (16.9) | 77 (36) | 0.0003 |
One-vessel disease, n (%) | 38 (38.4) | 50 (38.5) | 78 (36.4) | 0.912 |
Two-vessel disease, n (%) | 49 (49.5) | 62 (47.7) | 107 (50) | 0.916 |
Three-vessel disease, n (%) | 11 (11.1) | 20 (15.4) | 23 (10.7) | 0.414 |